316 related articles for article (PubMed ID: 15792818)
21. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
Ozekmekçi S; Apaydin H; Kiliç E
Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
Pantelatos A; Fornadi F
Adv Neurol; 1993; 60():690-7. PubMed ID: 8420212
[TBL] [Abstract][Full Text] [Related]
23. Female gender but not cigarette smoking delays the onset of Parkinson's disease.
Martínez-Rumayor A; Arrieta O; Sotelo J; García E
Clin Neurol Neurosurg; 2009 Nov; 111(9):738-41. PubMed ID: 19695769
[TBL] [Abstract][Full Text] [Related]
24. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
[TBL] [Abstract][Full Text] [Related]
25. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.
Wagner ML; Fedak MN; Sage JI; Mark MH
Ann Clin Lab Sci; 1996; 26(5):389-95. PubMed ID: 8879356
[TBL] [Abstract][Full Text] [Related]
26. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
27. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
28. [Levodopa and cognitive disorders in Parkinson's disease].
Leiva-Santana C; Alvarez-Saúco M
Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
[TBL] [Abstract][Full Text] [Related]
29. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
30. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
31. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
32. Management for motor and non-motor complications in late Parkinson's disease.
Chan DK; Cordato DJ; O'Rourke F
Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
[TBL] [Abstract][Full Text] [Related]
33. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
[TBL] [Abstract][Full Text] [Related]
35. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
[TBL] [Abstract][Full Text] [Related]
36. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
37. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
Cubo E; González M; Aguilar A; Quintana S
Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of Parkinson's disease in Northern Jordan.
Alrefai A; Habahbih M; Alkhawajah M; Darwish M; Batayha W; Khader Y; El-Salem K
Clin Neurol Neurosurg; 2009 Dec; 111(10):812-5. PubMed ID: 19733962
[TBL] [Abstract][Full Text] [Related]
39. Smoking and Parkinson's disease.
Mayeux R; Tang MX; Marder K; Côté LJ; Stern Y
Mov Disord; 1994 Mar; 9(2):207-12. PubMed ID: 8196685
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
